Citius Oncology (CTOR) Stock: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.58
-0.12 (-17.16%)
▼
5d:
-24.53%
30d:
-44.81%
90d:
+4.23%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CTOR is down 24.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CTOR is down 24.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.58, which is considered oversold relative to its 30-day fair value range of $0.74 to $1.03. From a valuation perspective, the stock is trading at a premium (Forward PE: 5.8) compared to its historical average (5.1). At these levels, the market is pricing in 4.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTOR is in a uptrend. Immediate support is located at $0.51, while resistance sits at $0.86. Short-term momentum is weak, with the stock down 17.2% recently.
Market Sentiment: CTOR scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+590.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTOR is in a uptrend. Immediate support is located at $0.51, while resistance sits at $0.86. Short-term momentum is weak, with the stock down 17.2% recently.
Market Sentiment: CTOR scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+590.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.74 -
$1.03
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-17.2%)
- BULLISH: Trading 590.3% below Wall St target ($4.00)
- NEUTRAL: Market pricing in 4.6% annual earnings growth - fairly valued
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.74 -
$1.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.51
Resistance Level
$0.86
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.79
Wall Street Target
$4.00
(+590.3%)
Valuation Premium vs History
+4.6% premium
PE vs Historical
5.8 vs 5.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.6%
(market-implied from PE analysis)
1-Year Target
$0.61
(+5%)
2-Year Target
$0.63
(+9%)
3-Year Target
$0.66
(+14%)
3-Yr Target (if PE normalizes)
(PE: 6→5)
PE COMPRESSION
$0.58
(+1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 24, 2026 9:51 AM ET
Data refreshes hourly during market hours. Next update: 10:51 AM
Data refreshes hourly during market hours. Next update: 10:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |